The 2023 PTSD guideline applied GRADE more rigorously than the 2017 version, according to the guideline. That resulted in some recommendations being downgraded as the evidence was reevaluated.<\/p>\n
Recommendations can change as research develops, and veteran-specific evidence can matter, too.<\/p>\n
Wiechers said evidence involving veterans can be an important consideration when VA evaluates whether a treatment should become available, even when research in other populations is promising.<\/p>\n
For PTSD, however, the 2023 VA\/DoD guideline says a lack of data on veterans or service members alone did not alter its recommendations. That helps explain why FDA approval and VA availability are not necessarily the same thing.<\/p>\n
How a treatment moves into VA care<\/p>\n
Repetitive transcranial magnetic stimulation, or rTMS, offers a concrete example of how the VA adopts a new treatment.<\/p>\n
The FDA approved rTMS for depression in 2008. According to VA, the department then conducted a large study involving veterans<\/a>, tested the treatment in a pilot program at 35 VA sites and expanded access after the pilot.<\/p>\n VA says more than 60 of its facilities now offer rTMS, with some operating specialized clinics that combine it with other advanced depression treatments. Dr. Wiechers added that the success of the program\u2019s original 35 clinics, as listed on the VA\u2019s website, resulted in the program expanding to over 60 facilities.<\/p>\n The sequence illustrates the difference between FDA approval and VA implementation. VA says it studied rTMS in its own patient population, tested its delivery across multiple facilities, and then expanded access.<\/p>\n There is no single office that makes the decision.<\/p>\n Dr. Wiechers described a team-based process in which draft policies are shared with offices responsible for delivering or overseeing a treatment. That allows potential risks, downsides and ethical concerns to be identified before policies are finalized.<\/p>\n Among the offices involved, Dr. Wiechers identified the Office of Mental Health<\/a> and its programs, including the National Center for PTSD; the Office of Suicide Prevention; Pharmacy Services; the National Center for Ethics in Health Care; Nursing Services; and Care Management & Social Work Services.<\/p>\n The considerations extend beyond whether a treatment works.<\/p>\n Wiechers said VA also considers whether it has enough trained clinicians, specialized equipment and space to deliver a treatment, as well as whether adding it could take resources away from other care.<\/p>\n For medications, another layer comes into play.<\/p>\n VA\u2019s National Formulary<\/a> establishes the department\u2019s national preferred list of medications. Some medications also have Criteria for Use documents that establish evidence-based conditions or restrictions for prescribing.<\/p>\n VA says medication reviews can be prompted by new FDA approvals or research that could affect evidence-based prescribing, clinical practice or health outcomes for veterans. <\/p>\n The formulary process includes VA physicians, Pharmacy Benefits Management officials and Veterans Integrated Service Network pharmacist executives. Formulary documents are reviewed, and feedback is solicited from health care teams.<\/p>\n An FDA-approved medication, therefore, can be available in civilian medicine while having different prescribing conditions inside VA.<\/p>\n That distinction can be particularly important for treatments that carry significant risks or require specialized monitoring.<\/p>\n Emerging treatments test the boundaries<\/p>\n Emerging mental health treatments illustrate the difference between scientific promise and routine clinical care.<\/p>\n The VA\/DoD PTSD guideline, for example, recommends against benzodiazepines for PTSD, citing a lack of evidence of benefit and known harms, such as drug dependence and addiction. <\/p>\n It also recommends against cannabis and cannabis-derived products for PTSD, citing a lack of well-designed randomized controlled trials and potentially serious side effects.<\/p>\n Veterans are questioning why their legal cannabis license can\u2019t be considered by the VA.<\/p>\n \u201cI have a medical cannabis license, and I have to pay for my medication out of pocket, but almost any other medication is covered by the VA,\u201d explained George Canfield, a retired Army veteran.<\/p>\n \u201cWhy can\u2019t VA offer some kind of subsidy to offset the cost of this naturally derived treatment? I don\u2019t expect a VA-run dispensary, but I would like it to be more affordable since it\u2019s what helps me more than any other medication I\u2019ve tried,\u201d he said. \u201cAnd I\u2019ve tried them all!\u201d<\/p>\n Ketamine presents a different example. The VA\/DoD guideline retained a weak recommendation against ketamine for PTSD, citing limitations in the evidence and a lack of demonstrated effectiveness for the condition.<\/p>\n Psychedelic-assisted therapies remain an area of active research, meaning promising findings do not by themselves establish a treatment as routine VA care. <\/p>\n VA has recently expanded its research into psychedelic therapies<\/a> and is recruiting veteran participants<\/a> for clinical trials in select regions.<\/p>\n For veterans, those distinctions can affect whether a treatment encountered outside VA is available or subject to different conditions within the federal health system.<\/p>\n What happens after a treatment works?<\/p>\n The process continues after a treatment enters clinical practice.<\/p>\n VA says it monitors treatments through individual reports of adverse events or other problems, ongoing quality monitoring and formal research.<\/p>\n If a patient experiences a bad reaction or other adverse outcome, local staff can report and investigate it. Dedicated safety programs can identify patterns that may warrant broader review or changes in guidance.<\/p>\n VA also evaluates how treatments perform in actual clinical practice, particularly when a new treatment is introduced or when policies governing its use change.<\/p>\n Once a treatment becomes standard care, researchers generally cannot create the same untreated comparison group used in many clinical trials.<\/p>\n Dr. Wiechers said the most rigorous safety and effectiveness checks tend to occur early, while a treatment is still being rolled out.<\/p>\n The process does not end there. VA and the Department of Defense periodically revisit clinical practice guidelines as evidence changes. The current 2023 VA\/DoD PTSD guideline contains 34 evidence-based recommendations and is intended to assist, rather than replace, clinical judgment. The guideline is a tool for clinicians and does not define required care. <\/p>\n What veterans see at the end of the process<\/p>\n For a veteran sitting across from a VA clinician, much of this process is invisible.<\/p>\n The veteran sees a treatment that is available, restricted, unavailable or offered only through a clinical trial.<\/p>\n Behind that decision may be years of research, clinical practice guidelines, formulary reviews, safety monitoring and assessments of whether VA can deliver the treatment.<\/p>\n Dr. Wiechers said there are several reasons why a treatment may not be available to veterans.<\/p>\n \u201cVA only offers treatments that have solid research behind them showing they help,\u201d she said. When a treatment is not available, she said, it may be because \u201cthe evidence isn\u2019t strong enough yet, or it hasn\u2019t been proven to work well specifically for Veterans.\u201d<\/p>\n There is no single moment when someone decides a treatment \u201cworks.\u201d<\/p>\n Instead, VA describes a sequence of decisions involving evidence, safety, effectiveness for veterans, clinical guidance, feasibility and resources. Once a treatment reaches the clinic, monitoring and research continue.<\/p>\n The system is designed to answer a question bigger than whether a treatment works:<\/p>\n Is there enough evidence that it works for veterans, can VA deliver it safely and effectively, and should it become part of routine care?<\/p>\n Natalie Oliverio is an independent journalist and Navy veteran who covers military and veterans\u2019 issues. Drawing on her experience as a talent executive and mentor, she writes about the policies, people and programs shaping the military community.<\/p>\n","protected":false},"excerpt":{"rendered":"For veterans seeking treatment for PTSD, depression, anxiety or substance use disorders, the question sounds simple: If a…\n","protected":false},"author":2,"featured_media":644404,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[276],"tags":[8514,8513,8511,8510,8512,18,135,19,17,167,502,8515,3160,171533,48296,272659,272658,15032],"class_list":["post-644403","post","type-post","status-publish","format-standard","has-post-thumbnail","category-mental-health","tag-circulated-air-force-times","tag-circulated-army-times","tag-circulated-marine-corps-times","tag-circulated-military-times","tag-circulated-navy-times","tag-eire","tag-health","tag-ie","tag-ireland","tag-mental-health","tag-mentalhealth","tag-military-times","tag-ptsd","tag-substance-use-disorders","tag-va","tag-va-ptsd-treatment","tag-veteran-mental-health-treatment","tag-veterans"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/644403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=644403"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/644403\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/644404"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=644403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=644403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=644403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"\"](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/08\/UIUIJ622GBAP5PJG45FPQXXAPY.jpg\")
U.S. Navy Lt. Meghan Quinn, a psychiatrist and chief of the Partial Hospitalization Program at Walter Reed, and Dr. Vanessa Torres-Llenza, staff psychiatrist at PHP, demonstrate the use of Transcranial Magnetic Stimulation. (Quinton Lyons\/DoD)<\/p>\n![\"\"](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/08\/45LP24UMAZDGFK6UPPEI5YY2KA.jpg\")
A Marine veteran holds a sign to show support for cannabis for post-traumatic stress disorder sufferers outside the State Capitol in Des Moines, Iowa, in 20215. (Michael Zamora\/The Des Moines Register via AP)<\/p>\n![\"\"](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/08\/AEPEMB5XWFCHPMNB6WT67G6R64.png\")
Psychedelic-assisted therapies are an area of active research, but promising findings do not establish a treatment as routine care within the Department of Veterans Affairs. (MAPS).<\/p>\n